Paul Baldrick

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3836686/publications.pdf

Version: 2024-02-01

40 papers	1,354 citations	394421 19 h-index	345221 36 g-index
41 all docs	41 docs citations	41 times ranked	1718 citing authors

#	Article	IF	Citations
1	Successful regulatory agency interaction â€“ A nonclinical regulatory strategist's perspective. Regulatory Toxicology and Pharmacology, 2022, 130, 105130.	2.7	1
2	Development of COVID-19 therapies: Nonclinical testing considerations. Regulatory Toxicology and Pharmacology, 2022, 132, 105189.	2.7	5
3	Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals. Journal of Applied Toxicology, 2021, 41, 95-104.	2.8	3
4	Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies. Regulatory Toxicology and Pharmacology, 2021, 121, 104869.	2.7	7
5	Core battery safety pharmacology testing â€“ An assessment of its utility in early drug development. Journal of Pharmacological and Toxicological Methods, 2021, 109, 107055.	0.7	7
6	Genotoxicity test battery â€“ An assessment of its utility in early drug development. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2021, 868-869, 503388.	1.7	4
7	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. Regulatory Toxicology and Pharmacology, 2020, 113, 104624.	2.7	22
8	Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future. Therapeutic Innovation and Regulatory Science, 2020, 54, 586-597.	1.6	0
9	Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future. Therapeutic Innovation and Regulatory Science, 2019, , 216847901986455.	1.6	1
10	Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development. Regulatory Toxicology and Pharmacology, 2019, 108, 104441.	2.7	0
11	New toxicity testing of PQ grass allergy immunotherapy to support product development. Journal of Applied Toxicology, 2019, 39, 1462-1469.	2.8	1
12	Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label. Therapeutic Innovation and Regulatory Science, 2018, 52, 641-648.	1.6	11
13	Reviewing the Utility of Two Species in General Toxicology Related to Drug Development. International Journal of Toxicology, 2018, 37, 121-124.	1.2	23
14	Pharmacokinetic and toxicology comparator testing of biosimilar drugs â€“ Assessing need. Regulatory Toxicology and Pharmacology, 2017, 86, 386-391.	2.7	8
15	Getting a molecule into the clinic: Nonclinical testing and starting dose considerations. Regulatory Toxicology and Pharmacology, 2017, 89, 95-100.	2.7	16
16	Dose site reactions and related findings after vaccine administration in safety studies. Journal of Applied Toxicology, 2016, 36, 980-990.	2.8	30
17	Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs, 2016, 8, 427-435.	5.2	32
18	Risk Management Plans in the European Union: Nonclinical Aspects. Therapeutic Innovation and Regulatory Science, 2016, 50, 101-105.	1.6	2

#	Article	IF	Citations
19	Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology, 2014, 70, 413-429.	2.7	22
20	Utility and importance of animal data in drug product labels. Regulatory Toxicology and Pharmacology, 2014, 69, 546-557.	2.7	7
21	The evolution of juvenile animal testing for small and large molecules. Regulatory Toxicology and Pharmacology, 2013, 67, 125-135.	2.7	14
22	A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of grass pollen allergy. Journal of Applied Toxicology, 2012, 32, 608-616.	2.8	8
23	The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates. Regulatory Toxicology and Pharmacology, 2012, 62, 347-354.	2.7	54
24	Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of grass pollen allergy. Reproductive Toxicology, 2011, 32, 322-328.	2.9	6
25	Safety evaluation of biological drugs: What are toxicology studies in primates telling us?. Regulatory Toxicology and Pharmacology, 2011, 59, 227-236.	2.7	42
26	The safety of chitosan as a pharmaceutical excipient. Regulatory Toxicology and Pharmacology, 2010, 56, 290-299.	2.7	460
27	Juvenile animal testing in drug development â€“ Is it useful?. Regulatory Toxicology and Pharmacology, 2010, 57, 291-299.	2.7	40
28	Safety evaluation to support first-in-man investigations II: Toxicology studies. Regulatory Toxicology and Pharmacology, 2008, 51, 237-243.	2.7	48
29	Safety evaluation to support First-In-Man investigations I: Kinetic and safety pharmacology studies. Regulatory Toxicology and Pharmacology, 2008, 51, 230-236.	2.7	16
30	Carcinogenicity Evaluation: Comparison of Tumor Data from Dual Control Groups in the CDâ€“1 Mouse. Toxicologic Pathology, 2007, 35, 562-575.	1.8	32
31	PollinexÂ® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of ragweed pollen allergy. Journal of Applied Toxicology, 2007, 27, 399-409.	2.8	32
32	Carcinogenicity Evaluation: Comparison of Tumor Data from Dual Control Groups in the Sprague–Dawley Rat. Toxicologic Pathology, 2005, 33, 283-291.	1.8	36
33	Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A(MPLÂ®) for the treatment of grass pollen allergy. Journal of Applied Toxicology, 2004, 24, 261-268.	2.8	20
34	Developing drugs for pediatric use: a role for juvenile animal studies?. Regulatory Toxicology and Pharmacology, 2004, 39, 381-389.	2.7	43
35	Toxicokinetics in preclinical evaluation. Drug Discovery Today, 2003, 8, 127-133.	6.4	35
36	Biological safety testing of polymers. Medical Device Technology, 2003, 14, 12-5.	0.1	0

#	Article	IF	Citations
37	Safety Evaluation of Monophosphoryl Lipid A (MPL): An Immunostimulatory Adjuvant. Regulatory Toxicology and Pharmacology, 2002, 35, 398-413.	2.7	83
38	Review ofL-tyrosine confirming its safe human use as an adjuvant. Journal of Applied Toxicology, 2002, 22, 333-344.	2.8	61
39	Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPLÂ®) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine, 2001, 20, 737-743.	3.8	29
40	Pharmaceutical Excipient Development: The Need for Preclinical Guidance. Regulatory Toxicology and Pharmacology, 2000, 32, 210-218.	2.7	84